Procter & Gamble Health Ltd announced an interim dividend of ₹160 per equity share for FY26, including a one-time special dividend of ₹50 per share. According to reports from ScanXNews, the dividend will be paid on or before March 4, 2026, with February 12, 2026 fixed as the record date. The company has issued comprehensive guidelines regarding Tax Deduction at Source (TDS) on dividend payments, with varying rates for different shareholder categories. Resident shareholders with PAN available will be taxed at 10% TDS, while those without PAN or with invalid PAN will face 20% TDS. Non-resident shareholders, including Foreign Institutional Investors (FII) and Foreign Portfolio Investors (FPI), will be subject to 20% TDS plus applicable surcharge and cess, or beneficial DTAA rates if eligible documentation is provided. Shareholders must submit required forms and documents by February 10, 2026 to avail appropriate TDS rates.
For the December quarter, P&G Health posted mixed operational results with net profit declining 14.7% year-on-year to ₹776 million, compared with ₹909 million in the corresponding period last year. As reported by ScanXNews, revenue from operations grew a healthy 20.7% year-on-year to ₹3,739 million, up from ₹3,098 million, indicating strong top-line momentum during the quarter. However, total expenses surged 40.3% to ₹2,694 million, significantly outpacing revenue growth and compressing margins. Profit Before Tax margin contracted significantly from 38.79% in Q3 FY25 to 28.77% in Q3 FY26, while Net Profit margin compressed from 28.97% to 20.51%. Earnings Per Share (EPS) for Q3 FY26 stood at ₹46.74, down 14.6% from ₹54.76 in the previous year, reflecting the impact of higher operational costs on profitability. The company's total dividend outflow amounts to ₹2,656 million, providing substantial value to shareholders despite operational cost pressures.
For the nine-month period (9M FY26), P&G Health demonstrated stronger overall performance with net profit growing 22.3% year-on-year to ₹2,323 million. According to ScanXNews, this growth was considerably aided by the absence of a ₹2,019 lakh exceptional item recognised in 9M FY25, which related to the discontinuation of injection production, asset sale, and impairment of the Goa plant. The company's Earnings Per Share (EPS) for 9M FY26 stood at ₹139.95, reflecting the improved profitability trend despite quarterly challenges. Revenue for 9M FY26 reached ₹10,375 million, showing a 14.4% year-on-year growth from ₹9,071 million in the corresponding period last year. The nine-month performance shows stronger profitability growth compared to the quarterly results, indicating improved operational efficiency over the extended period.
The Board of Directors approved the unaudited financial results at their meeting held on February 6, 2026, which commenced at 12:11 p.m. and concluded at 14:23 p.m. As reported by ScanXNews, the results have been prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and subjected to limited review by the company's statutory auditors. The company continues to focus on its pharmaceuticals segment as the single primary reportable business, having successfully transitioned its injection portfolio to contract manufacturing following the discontinuation of injection production at its Goa facility. The financial results reflect the company's strategic positioning in the healthcare sector with sustained revenue growth despite margin pressures in the current quarter.
Following the earnings announcement, shares of Procter & Gamble Health Ltd were trading 1.03% lower at ₹5,190 on the NSE, according to CNBC TV18. The mixed performance with strong revenue growth but declining profitability appears to have impacted investor sentiment despite the company's decision to declare a significant dividend. The total payout amounts to ₹26,559 lakhs, providing substantial value to shareholders despite operational cost pressures during the quarter. The divergence between strong revenue growth and declining quarterly profits is a key concern for investors, suggesting potential headwinds in cost management or competitive pressures affecting margins. Historical stock returns show -1.03% for 1 day, -3.02% for 5 days, -11.19% for 1 month, -15.92% for 6 months, -3.36% for 1 year, and -27.64% for 5 years, reflecting the challenging market conditions facing the healthcare sector.
